# US 2026/0151360 A1 · Endoxifen compositions and methods of use thereof and synthesis thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0151360 A1
- Document ID: US20260151360A1
- Status: Published application
- Kind: A1
- Application number: 19/452,023
- Filed: 2026-01-16
- Published: 2026-06-04
- Earliest claimed: 2023-07-19
- Assignees: Atossa Therapeutics, Inc.
- Applicants: Atossa Therapeutics, Inc.
- Inventors: Steven Carl QUAY
- Web page: https://patentgrep.com/patent/US20260151360A1

## CPC

- A61K 31/138: Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine (atenolol A61K31/165; pindolol A61K31/404; timolol A61K31/5377)
- A61K 31/015: carbocyclic
- A61K 31/14: Quaternary ammonium compounds, e.g. edrophonium, choline (betaines A61K31/205)
- A61K 31/165: having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K 31/265: of carbonic, thiocarbonic, or thiocarboxylic acids, e.g. thioacetic acid, xanthogenic acid, trithiocarbonic acid
- A61K 31/325: Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof (thiurams A61K31/145)
- A61K 31/343: condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- C07C 217/18: the six-membered aromatic ring or condensed ring system containing that ring being further substituted
- C07C 233/18: having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
- C07C 271/16: to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
- A61K 9/48: Preparations in capsules, e.g. of gelatin, of chocolate {(A61K9/0004 takes precedence; bite capsules A61K9/0056)}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS

## Abstract

Described herein are endoxifen compositions comprising novel compounds and methods of use thereof. Methods of synthesis for the compositions are described herein. The endoxifen compositions described herein may exhibit aromatase inhibition activity or estrogen receptor activity. The endoxifen compositions described herein may be useful in the treatment of a condition in a subject, such as cancer.

## Claims

### Claim at position 1

-139. (canceled)

### Claim 140

A composition comprising:
an endoxifen:
or a pharmaceutically acceptable salt thereof; and
not less than 0.01 wt % and not more than 1 wt % of
or a combination thereof.

### Claim 141 (depends on 140)

The composition of claim 140, wherein the composition further comprises not less than 0.01 wt % and not more than 1 wt % of a further component, wherein the further component comprises one or more of the following compounds, or a pharmaceutically acceptable salt of any one thereof:

### Claim 142 (depends on 140)

The composition of claim 140, wherein the endoxifen is not less than 95% (Z)-endoxifen:

### Claim 143 (depends on 140)

The composition of claim 140, wherein the endoxifen is not more than 2% (E)-endoxifen:

### Claim 144 (depends on 140)

The composition of claim 140, wherein the composition comprises not less than not less than 0.01% and not more than 0.1% of Compound 7a and Compound 7b.

### Claim 145 (depends on 141)

The composition of claim 141, wherein the composition comprises not less than 0.1% and not more than 1 wt % of Compound 1.

### Claim 146 (depends on 141)

The composition of claim 141, wherein the composition comprises not less than 0.1% and not more than 1 wt % of Compound 2.

### Claim 147 (depends on 141)

The composition of claim 141, wherein the composition comprises not less than 0.1% and not more than 1 wt % of Compound 3.

### Claim 148 (depends on 141)

The composition of claim 141, wherein the composition comprises not less than not less than 0.1% and not more than 1% of Compound 4a and Compound 4b.

### Claim 149 (depends on 141)

The composition of claim 141, wherein the composition comprises not less than not less than 0.01% and not more than 0.1% of Compound 5a and Compound 5b.

### Claim 150 (depends on 141)

The composition of claim 141, wherein the total wt % of the one or more compounds is less than or equal to 2 wt %.

### Claim 151 (depends on 140)

The composition of claim 140, wherein the composition has aromatase inhibition activity, an affinity to an estrogen receptor, or a combination thereof.

### Claim 152 (depends on 140)

The composition of claim 140, wherein the pharmaceutically acceptable salt of the endoxifen is selected from the group consisting of an arecoline, besylate, bicarbonate, bitartarate, butylbromide, citrate, camysylate, gluconate, glutamate, glycollylarsanilate, hexylresorcinate, hydrabamine, hydrobromide, hydrochloride, hydroxynapthanoate, isethionate, malate, mandelate, mesylate, methylbromide, methylnitrate, methylsulfate, mucate, napsylate, nitrate, pamaoate (Embonate), pantothenate, phosphate/diphosphate, polygalacuronate, salicylate, stearate, sulfate, tannate, Teoclate, triethiodide, benzathine, clemizole, chloroprocaine, choline, diethylamine, diethanolamine, ethylenediamine, meglumine, piperazine, procaine, aluminum, barium, bismuth, lithium, magnesium, potassium, and zinc salt.

### Claim 153 (depends on 152)

The composition of claim 152, wherein the pharmaceutically acceptable salt of the endoxifen is endoxifen gluconate, endoxifen citrate, or endoxifen hydrochloride.

### Claim 154 (depends on 142)

The composition of claim 142, wherein the (Z)-endoxifen is polymorphic Form I of (Z)-endoxifen that is characterized by an x-ray powder diffraction pattern comprising major peaks at 16.8±0.3°, 17.1±0.3°, and 21.8±0.3° two theta.

### Claim 155 (depends on 140)

The composition of claim 140, wherein the composition comprises from 0.01 mg to 200 mg of the endoxifen.

### Claim 156 (depends on 140)

The composition of claim 140, wherein the composition comprises less than 0.25% water content.

### Claim 157 (depends on 140)

The composition of claim 140, wherein the composition comprises less than:
6000 ppm methanol;
9000 ppm ethanol;
9000 ppm acetone;
9000 ppm isopropyl alcohol;
1000 ppm acetonitrile;
9000 ppm ethyl acetate;
1500 ppm tetrahydrofuran;
1500 ppm 2-methyltetrahydrofuran;
250 m benzene;
250 ppm mesityl oxide; or
any combinations thereof.

### Claim 158 (depends on 140)

The composition of claim 140, wherein the composition comprises less than:
less than 500 ppm zinc;
less than 500 ppm titanium; or
a combination thereof.

### Claim 159 (depends on 140)

The composition of claim 140, wherein the composition is formulated as a tablet or a capsule.

### Claim 160 (depends on 159)

The composition of claim 159, wherein the formulation is an enteric formulation.

### Claim 161 (depends on 159)

The composition of claim 159, wherein the formulation is a delayed-release formulation.

### Claim 162 (depends on 159)

The composition of claim 159, wherein the formulation comprises hydroxypropyl methyl cellulose.

### Claim 163 (depends on 140)

The composition of claim 140, wherein the composition is formulated as a pharmaceutical composition comprising the composition and a pharmaceutically acceptable excipient or diluent.

### Claim 164 (depends on 163)

The pharmaceutical composition of claim 163, wherein the pharmaceutical composition is administered to a subject in need thereof.

### Claim 165 (depends on 164)

The pharmaceutical composition of claim 164, wherein the subject in need thereof has or is at risk of having a hormone-dependent breast disorder, a hormone-dependent reproductive tract disorder, a depression, or any combinations thereof.

### Claim 166 (depends on 165)

The pharmaceutical composition of claim 165, wherein the hormone-dependent breast disorder or the hormone-dependent reproductive tract disorder is a benign breast disorder, hyperplasia, atypia, atypical ductal hyperplasia, atypical lobular hyperplasia, increased breast density, gynecomastia, DCIS, LCIS, breast cancer, precocious puberty, McCune-Albright Syndrome, endometrial cancer, ovarian cancer, uterine cancer, cervical cancer, vaginal cancer, or vulvar cancer.

### Claim 167 (depends on 164)

The pharmaceutical composition of claim 164, wherein the subject in need thereof has prostate cancer and has or is at risk of having gynecomastia.

### Claim 168 (depends on 164)

The pharmaceutical composition of claim 164, wherein the subject in need thereof has tamoxifen-refractory or tamoxifen resistant hormone-dependent breast disorder or hormone-dependent reproductive tract disorder.

### Claim 169 (depends on 164)

The pharmaceutical composition of claim 164, wherein the subject in need thereof is or will be treated with an SSRI drug selected from the group consisting of citalopram, escitalopram, fluoxetine, paroxetine, sertraline, and vilazodone.

### Claim 170 (depends on 164)

The pharmaceutical composition of claim 164, wherein the subject in need thereof is administered the pharmaceutical composition daily.

### Claim 171 (depends on 163)

The pharmaceutical composition of claim 163, wherein the pharmaceutical composition is used in a method of treating a hormone-dependent breast disorder, a hormone-dependent reproductive tract disorder, a depression, or any combinations thereof, the method comprising administration of an effective amount the pharmaceutical composition to a subject in need thereof, thereby treating the hormone-dependent breast disorder, the hormone-dependent reproductive tract disorder, a depression, or any combinations thereof.

### Claim 172 (depends on 171)

The pharmaceutical composition of claim 171, wherein the hormone-dependent breast disorder or the hormone-dependent reproductive tract disorder is a benign breast disorder, hyperplasia, atypia, atypical ductal hyperplasia, atypical lobular hyperplasia, increased breast density, gynecomastia, DCIS, LCIS, breast cancer, precocious puberty, McCune-Albright Syndrome, endometrial cancer, ovarian cancer, uterine cancer, cervical cancer, vaginal cancer, or vulvar cancer.

### Claim 173 (depends on 171)

The pharmaceutical composition of claim 171, wherein the subject in need thereof is tamoxifen-refractory or tamoxifen resistant.

### Claim 174 (depends on 171)

The pharmaceutical composition of claim 171, wherein the subject in need thereof is administered the pharmaceutical composition daily.

### Claim 175

A composition comprising:
an endoxifen:
or a pharmaceutically acceptable salt thereof; and
not less than 0.01 wt % and not more than 1 wt % of
or
a combination thereof.

### Claim 176 (depends on 175)

The composition of claim 175, wherein the composition further comprises not less than 0.01 wt % and not more than 1 wt % of a further component, wherein the further component comprises one or more of the following compounds, or a pharmaceutically acceptable salt of any one thereof:

### Claim 177 (depends on 175)

The composition of claim 175, wherein the endoxifen is not less than 95% (Z)-endoxifen:

### Claim 178 (depends on 175)

The composition of claim 175, wherein the endoxifen is not more than 2% (E)-endoxifen:

### Claim 179 (depends on 175)

The composition of claim 175, wherein the composition comprises not less than not less than 0.01% and not more than 0.1% of Compound 5a and Compound 5b.

### Claim 180 (depends on 176)

The composition of claim 176, wherein the composition comprises not less than 0.1% and not more than 1 wt % of Compound 1.

### Claim 181 (depends on 176)

The composition of claim 176, wherein the composition comprises not less than 0.1% and not more than 1 wt % of Compound 2.

### Claim 182 (depends on 176)

The composition of claim 176, wherein the composition comprises not less than 0.1% and not more than 1 wt % of Compound 3.

### Claim 183 (depends on 176)

The composition of claim 176, wherein the composition comprises not less than not less than 0.1% and not more than 1% of Compound 4a and Compound 4b.

### Claim 184 (depends on 176)

The composition of claim 176, wherein the composition comprises not less than not less than 0.01% and not more than 0.1% of Compound 7a and Compound 7b.

### Claim 185 (depends on 176)

The composition of claim 176, wherein the total wt % of the one or more compounds is less than or equal to 2 wt %.

### Claim 186 (depends on 175)

The composition of claim 175, wherein the composition has aromatase inhibition activity, an affinity to an estrogen receptor, or a combination thereof.

### Claim 187 (depends on 175)

The composition of claim 175, wherein the pharmaceutically acceptable salt of the endoxifen is selected from the group consisting of an arecoline, besylate, bicarbonate, bitartarate, butylbromide, citrate, camysylate, gluconate, glutamate, glycollylarsanilate, hexylresorcinate, hydrabamine, hydrobromide, hydrochloride, hydroxynapthanoate, isethionate, malate, mandelate, mesylate, methylbromide, methylnitrate, methylsulfate, mucate, napsylate, nitrate, pamaoate (Embonate), pantothenate, phosphate/diphosphate, polygalacuronate, salicylate, stearate, sulfate, tannate, Teoclate, triethiodide, benzathine, clemizole, chloroprocaine, choline, diethylamine, diethanolamine, ethylenediamine, meglumine, piperazine, procaine, aluminum, barium, bismuth, lithium, magnesium, potassium, and zinc salt.

### Claim 188 (depends on 187)

The composition of claim 187, wherein the pharmaceutically acceptable salt of the endoxifen is endoxifen gluconate, endoxifen citrate, or endoxifen hydrochloride.

### Claim 189 (depends on 177)

The composition of claim 177, wherein the (Z)-endoxifen is polymorphic Form I of (Z)-endoxifen that is characterized by an x-ray powder diffraction pattern comprising major peaks at 16.8±0.3°, 17.1±0.3°, and 21.8±0.3° two theta.

### Claim 190 (depends on 175)

The composition of claim 175, wherein the composition comprises from 0.01 mg to 200 mg of the endoxifen.

### Claim 191 (depends on 175)

The composition of claim 175, wherein the composition comprises less than 0.25% water content.

### Claim 192 (depends on 175)

The composition of claim 175, wherein the composition comprises less than:
6000 ppm methanol;
9000 ppm ethanol;
9000 ppm acetone;
9000 ppm isopropyl alcohol;
1000 ppm acetonitrile;
9000 ppm ethyl acetate;
1500 ppm tetrahydrofuran;
1500 ppm 2-methyltetrahydrofuran;
251 m benzene;
250 ppm mesityl oxide; or
any combinations thereof.

### Claim 193 (depends on 175)

The composition of claim 175, wherein the composition comprises less than:
less than 500 ppm zinc;
less than 500 ppm titanium; or
a combination thereof.

### Claim 194 (depends on 175)

The composition of claim 175, wherein the composition is formulated as a tablet or a capsule.

### Claim 195 (depends on 194)

The composition of claim 194, wherein the formulation is an enteric formulation.

### Claim 196 (depends on 194)

The composition of claim 194, wherein the formulation is a delayed-release formulation.

### Claim 197 (depends on 194)

The composition of claim 194, wherein the formulation comprises hydroxypropyl methyl cellulose.

### Claim 198 (depends on 175)

The composition of claim 175, wherein the composition is formulated as a pharmaceutical composition comprising the composition and a pharmaceutically acceptable excipient or diluent.

### Claim 199 (depends on 198)

The pharmaceutical composition of claim 198, wherein the pharmaceutical composition is administered to a subject in need thereof.

### Claim 200 (depends on 199)

The pharmaceutical composition of claim 199, wherein the subject in need thereof has or is at risk of having a hormone-dependent breast disorder, a hormone-dependent reproductive tract disorder, a depression, or any combinations thereof.

### Claim 201 (depends on 200)

The pharmaceutical composition of claim 200, wherein the hormone-dependent breast disorder or the hormone-dependent reproductive tract disorder is a benign breast disorder, hyperplasia, atypia, atypical ductal hyperplasia, atypical lobular hyperplasia, increased breast density, gynecomastia, DCIS, LCIS, breast cancer, precocious puberty, McCune-Albright Syndrome, endometrial cancer, ovarian cancer, uterine cancer, cervical cancer, vaginal cancer, or vulvar cancer.

### Claim 202 (depends on 199)

The pharmaceutical composition of claim 199, wherein the subject in need thereof has prostate cancer and has or is at risk of having gynecomastia.

### Claim 203 (depends on 199)

The pharmaceutical composition of claim 199, wherein the subject in need thereof has tamoxifen-refractory or tamoxifen resistant hormone-dependent breast disorder or hormone-dependent reproductive tract disorder.

### Claim 204 (depends on 199)

The pharmaceutical composition of claim 199, wherein the subject in need thereof is or will be treated with an SSRI drug selected from the group consisting of citalopram, escitalopram, fluoxetine, paroxetine, sertraline, and vilazodone.

### Claim 205 (depends on 199)

The pharmaceutical composition of claim 199, wherein the subject in need thereof is administered the pharmaceutical composition daily.

### Claim 206 (depends on 198)

The pharmaceutical composition of claim 198, wherein the pharmaceutical composition is used in a method of treating a hormone-dependent breast disorder, a hormone-dependent reproductive tract disorder, a depression, or any combinations thereof, the method comprising administration of an effective amount the pharmaceutical composition to a subject in need thereof, thereby treating the hormone-dependent breast disorder, the hormone-dependent reproductive tract disorder, a depression, or any combinations thereof.

### Claim 207 (depends on 206)

The pharmaceutical composition of claim 206, wherein the hormone-dependent breast disorder or the hormone-dependent reproductive tract disorder is a benign breast disorder, hyperplasia, atypia, atypical ductal hyperplasia, atypical lobular hyperplasia, increased breast density, gynecomastia, DCIS, LCIS, breast cancer, precocious puberty, McCune-Albright Syndrome, endometrial cancer, ovarian cancer, uterine cancer, cervical cancer, vaginal cancer, or vulvar cancer.

### Claim 208 (depends on 206)

The pharmaceutical composition of claim 206, wherein the subject in need thereof is tamoxifen-refractory or tamoxifen resistant.

### Claim 209 (depends on 206)

The pharmaceutical composition of claim 206, wherein the subject in need thereof is administered the pharmaceutical composition daily.

### Claim 210

A composition comprising:
an endoxifen:
or a pharmaceutically acceptable salt thereof; and
not less than 0.01 wt % and not more than 1 wt % of
a combination thereof.

### Claim 211 (depends on 210)

The composition of claim 210, wherein the composition further comprises not less than 0.01 wt % and not more than 1 wt % of a further component, wherein the further component comprises one or more of the following compounds, or a pharmaceutically acceptable salt of any one thereof:

### Claim 212 (depends on 210)

The composition of claim 210, wherein the endoxifen is not less than 95% (Z)-endoxifen:

### Claim 213 (depends on 210)

The composition of claim 210, wherein the endoxifen is not more than 2% (E)-endoxifen:

### Claim 214 (depends on 210)

The composition of claim 210, wherein the composition comprises not less than not less than 0.1% and not more than 1% of Compound 4a and Compound 4b.

### Claim 215 (depends on 211)

The composition of claim 211, wherein the composition comprises not less than 0.1% and not more than 1 wt % of Compound 1.

### Claim 216 (depends on 211)

The composition of claim 211, wherein the composition comprises not less than 0.1% and not more than 1 wt % of Compound 2.

### Claim 217 (depends on 211)

The composition of claim 211, wherein the composition comprises not less than 0.1% and not more than 1 wt % of Compound 3.

### Claim 218 (depends on 211)

The composition of claim 211, wherein the composition comprises not less than not less than 0.01% and not more than 0.1% of Compound 5a and Compound 5b.

### Claim 219 (depends on 211)

The composition of claim 211, wherein the composition comprises not less than not less than 0.01% and not more than 0.1% of Compound 7a and Compound 7b.

### Claim 220 (depends on 211)

The composition of claim 211, wherein the total wt % of the one or more compounds is less than or equal to 2 wt %.

### Claim 221 (depends on 210)

The composition of claim 210, wherein the composition has aromatase inhibition activity, an affinity to an estrogen receptor, or a combination thereof.

### Claim 222 (depends on 210)

The composition of claim 210, wherein the pharmaceutically acceptable salt of the endoxifen is selected from the group consisting of an arecoline, besylate, bicarbonate, bitartarate, butylbromide, citrate, camysylate, gluconate, glutamate, glycollylarsanilate, hexylresorcinate, hydrabamine, hydrobromide, hydrochloride, hydroxynapthanoate, isethionate, malate, mandelate, mesylate, methylbromide, methylnitrate, methylsulfate, mucate, napsylate, nitrate, pamaoate (Embonate), pantothenate, phosphate/diphosphate, polygalacuronate, salicylate, stearate, sulfate, tannate, Teoclate, triethiodide, benzathine, clemizole, chloroprocaine, choline, diethylamine, diethanolamine, ethylenediamine, meglumine, piperazine, procaine, aluminum, barium, bismuth, lithium, magnesium, potassium, and zinc salt.

### Claim 223 (depends on 222)

The composition of claim 222, wherein the pharmaceutically acceptable salt of the endoxifen is endoxifen gluconate, endoxifen citrate, or endoxifen hydrochloride.

### Claim 224 (depends on 212)

The composition of claim 212, wherein the (Z)-endoxifen is polymorphic Form I of (Z)-endoxifen that is characterized by an x-ray powder diffraction pattern comprising major peaks at 16.8±0.3°, 17.1±0.3°, and 21.8±0.3° two theta.

### Claim 225 (depends on 210)

The composition of claim 210, wherein the composition comprises from 0.01 mg to 200 mg of the endoxifen.

### Claim 226 (depends on 210)

The composition of claim 210, wherein the composition comprises less than 0.25% water content.

### Claim 227 (depends on 210)

The composition of claim 210, wherein the composition comprises less than:
6000 ppm methanol;
9000 ppm ethanol;
9000 ppm acetone;
9000 ppm isopropyl alcohol;
1000 ppm acetonitrile;
9000 ppm ethyl acetate;
1500 ppm tetrahydrofuran;
1500 ppm 2-methyltetrahydrofuran;
252 m benzene;
250 ppm mesityl oxide; or
any combinations thereof.

### Claim 228 (depends on 210)

The composition of claim 210, wherein the composition comprises less than:
less than 500 ppm zinc;
less than 500 ppm titanium; or
a combination thereof.

### Claim 229 (depends on 210)

The composition of claim 210, wherein the composition is formulated as a tablet or a capsule.

### Claim 230 (depends on 229)

The composition of claim 229, wherein the formulation is an enteric formulation.

### Claim 231 (depends on 229)

The composition of claim 229, wherein the formulation is a delayed-release formulation.

### Claim 232 (depends on 229)

The composition of claim 229, wherein the formulation comprises hydroxypropyl methyl cellulose.

### Claim 233 (depends on 210)

The composition of claim 210, wherein the composition is formulated as a pharmaceutical composition comprising the composition and a pharmaceutically acceptable excipient or diluent.

### Claim 234 (depends on 233)

The pharmaceutical composition of claim 233, wherein the pharmaceutical composition is administered to a subject in need thereof.

### Claim 235 (depends on 234)

The pharmaceutical composition of claim 234, wherein the subject in need thereof has or is at risk of having a hormone-dependent breast disorder, a hormone-dependent reproductive tract disorder, a depression, or any combinations thereof.

### Claim 236 (depends on 235)

The pharmaceutical composition of claim 235, wherein the hormone-dependent breast disorder or the hormone-dependent reproductive tract disorder is a benign breast disorder, hyperplasia, atypia, atypical ductal hyperplasia, atypical lobular hyperplasia, increased breast density, gynecomastia, DCIS, LCIS, breast cancer, precocious puberty, McCune-Albright Syndrome, endometrial cancer, ovarian cancer, uterine cancer, cervical cancer, vaginal cancer, or vulvar cancer.

### Claim 237 (depends on 234)

The pharmaceutical composition of claim 234, wherein the subject in need thereof has prostate cancer and has or is at risk of having gynecomastia.

### Claim 238 (depends on 234)

The pharmaceutical composition of claim 234, wherein the subject in need thereof has tamoxifen-refractory or tamoxifen resistant hormone-dependent breast disorder or hormone-dependent reproductive tract disorder.

### Claim 239 (depends on 234)

The pharmaceutical composition of claim 234, wherein the subject in need thereof is or will be treated with an SSRI drug selected from the group consisting of citalopram, escitalopram, fluoxetine, paroxetine, sertraline, and vilazodone.

### Claim 240 (depends on 234)

The pharmaceutical composition of claim 234, wherein the subject in need thereof is administered the pharmaceutical composition daily.

### Claim 241 (depends on 233)

The pharmaceutical composition of claim 233, wherein the pharmaceutical composition is used in a method of treating a hormone-dependent breast disorder, a hormone-dependent reproductive tract disorder, a depression, or any combinations thereof, the method comprising administration of an effective amount the pharmaceutical composition to a subject in need thereof, thereby treating the hormone-dependent breast disorder, the hormone-dependent reproductive tract disorder, a depression, or any combinations thereof.

### Claim 242 (depends on 241)

The pharmaceutical composition of claim 241, wherein the hormone-dependent breast disorder or the hormone-dependent reproductive tract disorder is a benign breast disorder, hyperplasia, atypia, atypical ductal hyperplasia, atypical lobular hyperplasia, increased breast density, gynecomastia, DCIS, LCIS, breast cancer, precocious puberty, McCune-Albright Syndrome, endometrial cancer, ovarian cancer, uterine cancer, cervical cancer, vaginal cancer, or vulvar cancer.

### Claim 243 (depends on 241)

The pharmaceutical composition of claim 241, wherein the subject in need thereof is tamoxifen-refractory or tamoxifen resistant.

### Claim 244 (depends on 241)

The pharmaceutical composition of claim 241, wherein the subject in need thereof is administered the pharmaceutical composition daily.
